Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H3HV
|
||||
| Former ID |
DIB003912
|
||||
| Drug Name |
AP-1030
|
||||
| Synonyms |
AP-1102; AP-1130; MS-05; Combined MC1/MC4 receptor agonists, Action Pharma; Melanocortin-1/-4 receptor agonists, ActionPharma; Melanocortin-1/melanocortin-4 receptor agonists, Action Pharma
|
||||
| Indication | Metabolic disorders [ICD9: 270-279; ICD10:E70-E89] | Phase 1/2 | [1], [2] | ||
| Company |
Action Pharma A/S
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
C1CN([C@@H](C1)C(=O)N[C@H](C(=O)N)C(C)C)C(=O)[C@@H](NC(<br />=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]<br />(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC<br />(=O)[C@@H](N)CO)CO)[C@@H](C)CC)[C@@H](C)CC)CO)Cc1c[nH]c<br />n1)Cc1ccccc1)CCCNC(=N)N)Cc1c[nH]c2c1cccc2)CCCCN
|
||||
| Target and Pathway | |||||
| Target(s) | Melanocyte stimulating hormone receptor | Target Info | Modulator | [3] | |
| Melanocortin-4 receptor | Target Info | Modulator | [3] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Melanogenesishsa04080:Neuroactive ligand-receptor interaction | |||||
| Pathway Interaction Database | Syndecan-3-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (s) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
| G alpha (s) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00464958) One Year Extension Study To Protocol C2/5/TZ:MS-05. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1322). | ||||
| REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.